ME/CFS in Germany: 650,000 Affected Individuals, Three Clinics, A Structural Failure

This article was created with AI support (Claude Sonnet 4.6) and editorially curated by Lukas Geiger. Foundation: three research reports on care provision, societal impact, and affected individuals’ perspectives (April 2026), as well as a literature corpus of 82 scientific papers on ME/CFS pathophysiology (2021–2026). The cited sources are listed in the bibliography at the end of this article.

The Numbers First

650,000 people in Germany live with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) — this is the first comprehensive modeling for Germany, developed by the ME/CFS Research Foundation together with Risklayer in 2025. Before the pandemic, the figure was around 400,000. The increase comes from post-COVID cases: a prospective U.S. cohort study (RECOVER-Adult, Journal of General Internal Medicine 2025, n > 13,000) puts the risk of ME/CFS after SARS-CoV-2 infection at 4.93 times that of uninfected individuals.

For these 650,000 affected individuals, there are only three dedicated specialized clinics for adults in the whole of Germany — the Charité Fatigue Center (CFC) in Berlin, which accepts only patients from Berlin and Brandenburg, the ME/CFS clinic at the Central Institute for Mental Health (ZI) Mannheim, and the Munich Chronic Fatigue Center (MCFC) at TU Munich, which specializes in children, adolescents, and young adults. That is the entire care structure — one clinic per roughly 200,000 affected individuals, one of which is reachable only regionally.

63.1 billion euros — this is the total societal damage that the ME/CFS Research Foundation and Risklayer (2025) calculate for Germany in 2024: direct treatment costs, care costs, productivity losses, social benefits, tax shortfalls. That corresponds to 1.5 percent of GDP. Against this sum stands just 15 to 20 million euros in annual research funding — a ratio of roughly 1 to 3,500.

63 percent of affected individuals initially receive a misdiagnosis, frequently depression, burnout, or somatization disorder — documented in a qualitative public health study from the German-speaking region (Habermann-Horstmeier & Horstmeier 2023, PMC10824585). The misdiagnosis is not merely a bureaucratic irritation. Treating ME/CFS as deconditioning and prescribing activating therapies systematically worsens patients’ condition — because post-exertional malaise (PEM) is the cardinal symptom of the disease, and physical exertion beyond a patient’s individual limit is precisely what triggers it.

What ME/CFS Is — Without Preamble

ME/CFS is a severe systemic disease whose defining feature is post-exertional malaise: a deterioration of condition that characteristically sets in 24 to 72 hours after physical or cognitive exertion, delayed, and can last for days to weeks. Further core symptoms are non-restorative sleep, cognitive impairment (so-called “brain fog”), and often orthostatic intolerance — symptoms worsening while standing.

The cardinal symptom PEM distinguishes ME/CFS from secondary exhaustion in heart failure, anemia, or depression. Davenport and Scheibenbogen stated explicitly in 2025 in Nature Communications: exercise intolerance in ME/CFS is not a consequence of inactivity. It is a matter of “altered effort, not deconditioning” — the capacity itself is impaired, not the fitness level.

ME/CFS disproportionately affects women: the gender ratio consistently runs 3:1 to 4:1. The second peak in disease onset occurs at age 30 to 39 — right in the middle of the core working-age years (Norwegian registry study, BMC Medicine 2014). Approximately 25 percent of affected individuals are housebound or bedridden; they also carry the largest share of the care burden, for which reliable figures for Germany are lacking.

The Care Situation in Germany 2024–2026

Clinics for One-Fifth of the Population

For adults with ME/CFS, there are three dedicated specialized clinics in Germany. The Charité Fatigue Center (CFC) in Berlin — the central point of contact since 2018, directed by Prof. Dr. Carmen Scheibenbogen — accepts only patients from Berlin and Brandenburg. The ME/CFS clinic at the Central Institute for Mental Health (ZI) Mannheim explicitly accepts ME/CFS patients, including those without a post-COVID trigger. The MCFC in Munich is pediatrically focused.

In addition, several university hospitals have set up post-COVID clinics — including LMU Munich, University Hospital Cologne, University Hospital Heidelberg, University Hospital Jena, and MHH Hannover. Whether these facilities accept patients who fell ill before the pandemic, and whether they have sufficient ME/CFS expertise, is largely not made clear on their websites. They should be understood as a secondary structure, not as an equivalent alternative to specialized care.

For adults outside Berlin-Brandenburg and Mannheim, there is practically no reliable care structure at all. The German Society for ME/CFS describes the situation on its website as a “care desert” (mecfs.de/versorgungswueste).

When three regionally bound clinics are supposed to serve 650,000 people, the waiting list is not an organizational problem. It is a structural failure.

Diagnostic Odyssey

IQWiG (the Institute for Quality and Efficiency in Health Care) found in its final report from May 2023 that ME/CFS is not anchored in the medical curriculum and that few physicians have sufficient knowledge of the disease. The consequence: according to Habermann-Horstmeier & Horstmeier (2023), over 63 percent of affected individuals initially receive a psychiatric or psychosomatic misdiagnosis — most often depression (36.6 percent of documented misdiagnoses), followed by burnout, adjustment disorder, and somatization disorder.

Wrongly prescribed activating therapies such as Graded Exercise Therapy (GET) demonstrably worsen the condition by provoking PEM. Affected individuals report that the ongoing failure to have their illness recognized in clinical encounters becomes, for some, a risk factor for suicidal ideation (Habermann-Horstmeier & Horstmeier 2023).

Until the end of 2025, ME/CFS was coded under G93.3 (postviral fatigue syndrome). As of January 1, 2026, a new differentiation applies in the ICD-10-GM:

G93.30 — Chronic Fatigue Syndrome, postinfectious
G93.31 — ME/CFS, non-postinfectious / other known cause
G93.39 — ME/CFS, unspecified

This differentiation enables, for the first time, clean epidemiological recording. Whether physicians will consistently apply the new codes in practice remains open — so far the diagnosis has often gone uncoded, or been subsumed under burnout (Z73.0).

ME/CFS is not listed as its own entry in the GdB table (Grad der Behinderung, degree of disability) of the Versorgungsmedizinische Grundsätze (Germany’s official disability-assessment guidelines), which makes assessments for severe-disability applications largely arbitrary. Since a position paper from January 2023, the German Pension Insurance (Deutsche Rentenversicherung) has recommended an interdisciplinary assessment with PEM as a mandatory component — but it does not publish concrete approval rates. Legal practice (attorney Frank Vormbaum, Werne) shows that disability pensions, even in severe ME/CFS, are routinely granted only on a temporary basis at first, forcing affected individuals into an endless loop of assessments and reapplications.

Two precedent-setting rulings from the social courts mark a shift: the Higher Social Court (LSG) of Baden-Württemberg found in November 2024 that ME/CFS can justify a disability pension (L 8 R 3110/22). The Higher Social Court (LSG) of Berlin-Brandenburg recognized in November 2025 that ME/CFS following a fifth disease (erythema infectiosum) infection qualifies as an occupational disease (L 3 U 206/19). Both are individual-case decisions, not systematic recognition.

Statutory Health Insurance Exclusion of Effective Therapies

Immunoadsorption and immunapheresis — procedures in which autoantibodies are filtered out of the blood, and which show symptom relief in some patients — are routinely rejected by the statutory health insurers. The justification: no completed studies, no established statutory-insurance standard. Affected individuals seeking access to these procedures pay several thousand euros per treatment cycle out of their own pocket.

Children and Adolescents

An estimated 40,000 children and adolescents in Germany are affected by ME/CFS (ME/CFS Research Foundation 2025). Pediatric care has changed substantially since late 2024 — a sharp contrast to the stagnation in adult care.

The MCFC in Munich was long the only specialized pediatric clinic nationwide. Since December 1, 2024, the BMG-funded PEDNET-LC network has been active: 20 pediatric competence centers across 15 federal states, 38 participating institutions, funded through 2028 with around 41 million euros. Locations include Berlin, Bielefeld, Bremen, Dresden, Essen, Freiburg, Hamburg, Hannover, Jena, Cologne, Munich, Rostock, and others. In addition, the state-funded project MOVE-ME/CFS-BW is building out five sociopediatric centers at university children’s hospitals in Baden-Württemberg — Freiburg, Heidelberg, Tübingen, Ulm, and Stuttgart.

These structures do not amount to comprehensive nationwide coverage. Capacity and wait times are still being built up, and ME/CFS-specific training at the centers is still underway. But the nationwide build-out of a specialized network for children is real — and there is no equivalent for adult care.

Affected children still miss months or years of school; accommodations fail because schools lack basic knowledge about PEM. For now, none of these new structures change that everyday reality — until the centers are established and known.

What Has Changed Politically

The G-BA Guideline and ICD Reform

The Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) adopted a guideline on December 21, 2023 for coordinated, cross-disciplinary care for suspected Long COVID (G-BA decision 6374). It took effect on May 9, 2024, and has been billable under the EBM (Einheitlicher Bewertungsmaßstab, the standard fee schedule for statutory health insurance) since January 1, 2025 — meaning contracted physicians can now bill for ME/CFS-specific services under new billing codes.

This is more than a bureaucratic step. The guideline anchors ME/CFS in statutory health insurance standard care for the first time — explicitly regardless of trigger. Patients who fell ill before the pandemic are included as well. This means ME/CFS is no longer dependent solely on specialized clinics or study enrollment; in principle, any contracted physician can now initiate the diagnostic workup.

Its practical reach has limits: the guideline covers diagnostic workup, not specialized care. Severely affected patients who cannot travel to a practice remain out of its reach on their own. The German Society for ME/CFS regards the guideline as an important step, but points to the still-unresolved capacity problem.

BMG Model Projects: New Care Approaches Under Development

Alongside the G-BA guideline, nine model projects of the Federal Ministry of Health (Module 1) have been running since 2024/25 across eight federal states — Baden-Württemberg, Bavaria, Berlin, Hamburg, Hesse, Mecklenburg-Vorpommern, Lower Saxony, and North Rhine-Westphalia. They test different approaches: telemedical diagnostics, interdisciplinary networks, coordinated care access.

The most concretely developed project is PAIS Care Berlin: starting in May 2025, the Charité is networking roughly 100 primary-care practices with the Charité Fatigue Center, funded with around 10 million euros. This is a new care model — not standard care, but substantially more than the previous situation, in which the CFC operated largely in isolation from ambulatory care.

Importantly: these are research projects with a care component. Whether and when their results feed into standard care depends on political decisions to be made after 2028.

National Decade Against Post-Infectious Diseases

In November 2025, the Federal Ministry of Research (BMFTR, Minister Dorothee Bär) announced the National Decade Against Post-Infectious Diseases for the period 2026–2036: 500 million euros for research and therapeutic measures on Long COVID, ME/CFS, and related conditions. 50 million euros are available initially in 2026; a steering committee set out initial measures in February 2026, including a biomarker database with genome sequencing.

In parallel, the Federal Ministry of Health is funding 34 care projects on Long COVID and ME/CFS through 2028, with a total of around 118 million euros.

The Alliance for Post-Infectious Diseases, convened by Health Minister Nina Warken and Research Minister Bär, includes Fatigatio e.V. and the German Society for ME/CFS as patient-advocacy partners.

Assessment

This amounts to a structural shift in state attention — and, in some areas, in the care structure itself. For children and adolescents, a nationwide competence network has emerged since late 2024. The G-BA guideline opens up standard care on paper. The model projects are testing new network models.

For adults outside the handful of specialized sites, none of this has yet translated into a noticeable improvement. Research funding is flowing into basic research and biomarker infrastructure. Specialized clinics do not automatically follow from that. The gap between care structures and political announcements will be felt for years to come.

What Research Knows

Five core findings from the international research field — condensed, not exhaustive:

Post-exertional malaise is measurable. The 2-Day CPET protocol (Two-Day Cardiopulmonary Exercise Test) makes the exercise intolerance objective: on the second CPET the following day, ME/CFS patients show a marked drop in peak oxygen uptake that does not occur in healthy controls. The NIH Deep Phenotyping Study (Walitt and Nath, Nature Communications 2024) provides the most extensive controlled phenotyping to date.

Cerebral hypoperfusion under orthostatic stress. Between 2022 and 2025, van Campen and Visser documented in several studies a cerebral blood-flow reduction of roughly 25 to 30 percent during tilt-table testing in ME/CFS patients — compared to around 7 percent in healthy controls. Christopoulos and Armstrong (2025) confirmed this pattern in a systematic review.

Mitochondrial supercomplex dysfunction. Wang and Nath published a causal finding in PNAS in 2023: under stress, the protein WASF3 disrupts formation of the mitochondrial complex III/IV supercomplex and throttles ATP output. WASF3 knockdown in a mouse model reproduces the fatigue phenotype. This is not merely an association.

Autoantibodies against vascular receptors. The Charité group led by Carmen Scheibenbogen has demonstrated functionally active autoantibodies against G-protein-coupled receptors (β2AdR, muscarinic receptors M3/M4, AT1R) in ME/CFS. Stein and Scheibenbogen showed in 2024 that immunoadsorption — filtering out these antibodies — leads to clinical improvement in 50 to 60 percent of treated patients. Causality has not yet been established by a placebo-controlled trial.

Endothelial dysfunction. Sandvik and colleagues (2023) documented endothelial impairment at the microvascular level. Wirth and Loehn (2023, 2024) linked this finding mechanistically: the dysfunction explains why muscles and brain are not adequately perfused under exertion.

The Integrating Hypothesis: The Wirth-Scheibenbogen Model

In several publications from 2021 to 2025, Wirth and Scheibenbogen have developed a mechanistic chain linking these findings: a triggering infection — SARS-CoV-2, EBV, Borrelia — induces autoantibodies against β2AdR. These block adrenaline-mediated vasodilation of the arterioles. Muscle tissue becomes underperfused under exertion; local ATP depletion sets in; calcium overload damages the mitochondria and drives supercomplex dissociation — precisely what Wang and Nath described at the molecular level in 2023. Clinically, patients experience this as post-exertional malaise.

The model links autoimmunity, vasculopathy, mitochondriopathy, and muscle pathology in a single chain. It does not explain why only some infected people become ill. It does not explain the gender asymmetry. But it points to where therapies might intervene: at the antibodies (immunoadsorption, daratumumab) or downstream, in ion metabolism (the mitodicure approach).

What Remains Open

Three fundamental gaps:

Why does only some fraction fall ill? According to the RECOVER-Adult study (2025), about 4.5 percent develop ME/CFS after SARS-CoV-2 infection; the other 95 percent do not. Nobody knows why. What is missing is a prospective cohort with a pre-infection baseline — genetic, immunological, mitochondrial — that could illuminate the selection event from the inside.

What comes first? Autoantibodies, mitochondrial dysfunction, and vascular impairment correlate with one another. The temporal sequence in the first year after infection has not been resolved. Anyone who wants to treat the disease causally needs to know where in the chain they are intervening.

Subtypes are missing. ME/CFS is probably not a single uniform picture but a phenotypic endpoint fed by several tributaries — post-COVID, post-EBV, post-Borrelia, with and without POTS, with and without an autoantibody profile. BioMapAI (Xiong, Nature Medicine 2025) and machine-learning approaches (Huang/Armstrong 2025) hint at clusters, but without external validation. Without a subtype taxonomy that can achieve consensus, therapy trials will keep enrolling heterogeneous cohorts and diluting effects. That may well have been the problem with rituximab, whose Phase III trial came back negative even though the Phase II data had shown responder rates of 65 percent.

What Is Needed Now

The research picture and the care data together point to a concrete list of measures:

More specialized clinics. Three clinics for 650,000 affected individuals — one of them restricted to the Berlin-Brandenburg region — is not a quality problem, it is a capacity problem. The ongoing model projects and the PEDNET-LC network for children show that building this out is possible. An equivalent care network for adults is missing. It would be a precondition for the political announcements of the National Decade to actually reach affected individuals.

A sham-controlled immunoadsorption study. It would clarify whether the autoantibodies are causal or merely epiphenomena — and would form the basis for statutory health insurance reimbursement in patients with a positive autoantibody finding. Without this study, immunoadsorption and related procedures remain an out-of-pocket expense.

A prospective post-infection cohort with a pre-infection baseline. The only method to understand the selection mechanism — and thereby to develop preventive strategies.

Social-law recognition without individual-case proceedings. Adding ME/CFS to the GdB table of the Versorgungsmedizinische Grundsätze and establishing permanent disability pensions as the rule rather than the exception would relieve both affected individuals and the courts.

Statutory health insurance reimbursement for immunoadsorption. Given the current state of research, a biologically plausible target exists in patients with a positive autoantibody finding. Under these conditions, refusing reimbursement is not an evidence-based decision — it is a fiscal one.

Conclusion

650,000 affected individuals. Three specialized clinics for adults, regionally bound. 20 new pediatric competence centers. Nine model projects under development. 63 billion euros in societal damage every year. A National Decade with 500 million euros, starting in 2026 and ending in 2036.

In recent years, research has uncovered biological mechanisms on several levels — mitochondria, vasculature, autoimmunity, the autonomic nervous system. The Wirth-Scheibenbogen model offers the most plausible framework so far for connecting these findings. A causal therapy backed by Phase III evidence does not yet exist.

What is moving in care provision is a mixed picture: in pediatrics, a nationwide network has emerged since late 2024. Politically and in regulatory terms, more has happened than in the ten years before. For adults outside Berlin-Brandenburg and Mannheim, none of this has changed anything so far. Three clinics for 650,000 affected individuals remain a structural failure — even as the field is being built out.

Methodological Note

This article draws on three editorial research reports on ME/CFS in Germany, produced in April 2026 (care provision, societal impact, affected individuals’ perspective), as well as a literature corpus of 82 scientific papers on the causes and pathophysiology of ME/CFS (primarily 2021–2026). Care-provision figures, funding amounts, and political developments come from verified German primary sources (IQWiG, G-BA, BMBF, BMFTR, BMG, BfArM, DRV, Fatigatio, German Society for ME/CFS, ME/CFS Research Foundation). The epidemiological modeling (650,000 affected individuals, 63.1 billion euros) is based on the first comprehensive German cost study by the ME/CFS Research Foundation / Risklayer (2025) — methodologically transparent, but not yet published in a peer-reviewed journal; it is considered the best current estimate, not epidemiological evidence of the highest quality. All figures cited in the text are documented in the bibliography. Where the evidence is uncertain, this has been flagged in the text.

Modified: 2026-04-20 (CL) — Care structure differentiated: ZI Mannheim added as third adult clinic; pediatric competence centers (PEDNET-LC, MOVE-ME/CFS-BW), BMG model projects, and G-BA standard care detailed further.

Bibliography

Federal Ministry of Health (Bundesgesundheitsministerium) (2024). Module 1: Model Projects for Integrated Care (Long/Post-COVID and ME/CFS). https://www.bundesgesundheitsministerium.de/ministerium/ressortforschung/handlungsfelder/forschungsschwerpunkte/long-/post-covid/modul-1

Federal Ministry of Health (Bundesgesundheitsministerium) (2024). PEDNET-LC — Pediatric Competence Network Long-COVID. Funding announcement, launched 01.12.2024, 20 centers in 15 federal states, 38 institutions. https://www.bundesgesundheitsministerium.de/ministerium/ressortforschung/handlungsfelder/forschungsschwerpunkte/long-/post-covid/modul-1-kiju/pednet-lc

Charité — Universitätsmedizin Berlin (2025). PAIS Care Berlin: Networking Primary-Care Practices with the Charité Fatigue Center. Press release, launched May 2025. https://www.charite.de/service/pressemitteilung/artikel/detail/mehr_unterstuetzung_fuer_long_covid_erkrankte

G-BA (2024). Guideline of the Federal Joint Committee on Coordinated, Cross-Disciplinary Care for Suspected Long-COVID (Decision 6374, 21.12.2023, in force 09.05.2024, billable under the EBM as of 01.01.2025). https://www.g-ba.de/beschluesse/6374/

MOVE-ME/CFS-BW (2024). Improving Care for Children and Adolescents with ME/CFS in Baden-Württemberg. State-funded project, 5 sociopediatric centers. https://move-me-cfs.de/ueber-uns

Ministry of Social Affairs Baden-Württemberg (2024). State Expands Care for Children and Adolescents with Post-Infectious Syndrome. Press release. https://sozialministerium.baden-wuerttemberg.de/de/service/presse/pressemitteilung/pid/land-baut-versorgung-von-kindern-und-jugendlichen-mit-postinfektioesem-syndrom-aus

ZI Mannheim (2024). Clinic for Post-COVID and ME/CFS. Central Institute for Mental Health Mannheim. https://www.zi-mannheim.de/en/patient-care/central-patient-admission-outpatient-departments/translate-to-english-ambulanz-fuer-post-covid-und-me/cfs.html

Fehrer A et al. (2026). Expert perspectives on ME/CFS — Insights from the 3rd International Conference of the Charité Fatigue Center. Autoimmunity Reviews, 25(5), 104043. doi:10.1016/j.autrev.2026.104043

Habermann-Horstmeier L, Horstmeier LM (2023). Systems thinking, subjective findings and diagnostic “pigeonholing” in ME/CFS: A qualitative public health study from a patient perspective. Deutsche Medizinische Wochenschrift, 149(4), e19–e36. doi:10.1055/a-2197-6479 (PMC10824585)

Hoffmann K, Hainzl A, Stingl M et al. (2024). Interdisciplinary, collaborative D-A-CH consensus statement on the diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Wiener klinische Wochenschrift, 136(Suppl 5), 103–112. doi:10.1007/s00508-024-02372-y (PMC11093804)

IQWiG (2023). Final Report ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome). Institute for Quality and Efficiency in Health Care, 15.05.2023. https://www.iqwig.de

ME/CFS Research Foundation / Risklayer (2025). The Rising Cost of Long COVID and ME/CFS in Germany. First comprehensive cost study for Germany (modeling; not yet in a peer-reviewed journal). https://mecfs-research.org/en/costreport-long-covid-and-mecfs/

NIH / RECOVER-Adult Study (2025). Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis. Journal of General Internal Medicine. doi:10.1007/s11606-024-09290-9 (PubMed-ID: 39804551)

Pheby DFH et al. (2020). The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of ME/CFS: A Report from EUROMENE. Healthcare (Basel), 8(2), 88. doi:10.3390/healthcare8020088 (PubMed-ID: 32272608)

Pheby DFH et al. (2021). The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from EUROMENE. Medicina (Kaunas), 57(4), 388. doi:10.3390/medicina57040388 (PubMed-ID: 33923830)

Stevelink SAM et al. (2022). Chronic fatigue syndrome and occupational status: a retrospective longitudinal study. Occupational Medicine, 72(3), 177–183. doi:10.1093/occmed/kqab170 (PubMed-ID: 34865116)

Scientific Papers (Pathophysiology)

Arron HE, Marsh BD, Kell DB, Khan MA, Jaeger BR, Pretorius E (2024). Myalgic encephalomyelitis/chronic fatigue syndrome: the biology of a neglected disease. Frontiers in Immunology, 15, 1386607. doi:10.3389/fimmu.2024.1386607

Castro-Marrero J, Segundo MJ, Lacasa M, Martinez-Martinez A, Sentañes RS, Alegre-Martin J (2021). Effect of dietary coenzyme Q10 plus NADH supplementation on fatigue perception and health-related quality of life in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: a prospective, randomized, double-blind, placebo-controlled trial. Nutrients, 13(8), 2658. doi:10.3390/nu13082658

Choutka J, Jansari V, Hornig M, Iwasaki A (2022). Unexplained post-acute infection syndromes. Nature Medicine, 28, 911–923. doi:10.1038/s41591-022-01810-6

Christopoulos EM, Tantanis D, Huang K et al. (2025). Mapping cerebral blood flow in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and orthostatic intolerance: insights from a systematic review. Journal of Translational Medicine, 23, 963. doi:10.1186/s12967-025-06954-w

Davenport TE, Scheibenbogen C, Zinn MA et al. (2025). Altered effort and deconditioning are not valid explanations of myalgic encephalomyelitis/chronic fatigue syndrome. Nature Communications, 16, 9176. doi:10.1038/s41467-025-64538-0

Davis HE, McCorkell L, Vogel JM, Topol EJ (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21, 133–146. doi:10.1038/s41579-022-00846-2

Fineschi S, Klar J, Lopez Egido JR et al. (2025). Comprehensive transcriptome assessment in PBMCs of post-COVID patients at a median follow-up of 28 months after a mild COVID infection reveals upregulation of JAK/STAT signaling and a prolonged immune response. Frontiers in Immunology, 16, 1589589. doi:10.3389/fimmu.2025.1589589

Fluge Ø, Mella O, Rekeland IG et al. (2025). Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome — a clinical pilot study. Frontiers in Medicine, 12, 1607353. doi:10.3389/fmed.2025.1607353

Greene C, Connolly R, Brennan D et al. (2024). Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nature Neuroscience, 27(3), 421–432. doi:10.1038/s41593-024-01576-9

Guo C, Che X, Briese T et al. (2023). Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host & Microbe, 31(2), 288. doi:10.1016/j.chom.2023.01.004

Hoel A, Hoel F, Dyrstad SEF et al. (2026). Charting the circulating proteome in ME/CFS using cross-system profiling to uncover mechanistic insights. Cell Reports Medicine, 102647. doi:10.1016/j.xcrm.2026.102647

Huang K, Lidbury BA, Thomas N et al. (2025). Machine learning and multi-omics in precision medicine for ME/CFS. Journal of Translational Medicine, 23, 68. doi:10.1186/s12967-024-05915-z

Joseph P, Arevalo C, Oliveira RKF et al. (2021). Insights from invasive cardiopulmonary exercise testing of patients with myalgic encephalomyelitis/chronic fatigue syndrome. CHEST, 160(2), 642–651. doi:10.1016/j.chest.2021.01.082

Liu Z, Hollmann G, Prusty BK et al. (2026). Immunoglobulin G complexes from post-infectious ME/CFS, including post-COVID ME/CFS disrupt cellular energetics and alter inflammatory marker secretion. Brain, Behavior, & Immunity – Health, 101187. doi:10.1016/j.bbih.2026.101187

Löhn M, Wirth KJ (2024). Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone. Journal of Translational Medicine, 22, 630. doi:10.1186/s12967-024-05412-3

Nakatomi Y, Mizuno K, Ishii A et al. (2014). Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an ¹¹C-(R)-PK11195 PET study. Journal of Nuclear Medicine, 55(6), 945–950. doi:10.2967/jnumed.113.131045

Rekeland IG, Sørland K, Neteland LL et al. (2024). Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in myalgic encephalomyelitis/chronic fatigue syndrome. PLOS One, 19(7), e0307484. doi:10.1371/journal.pone.0307484

Sandvik MK, Sørland K, Leirgul E et al. (2023). Endothelial dysfunction in ME/CFS patients. PLOS One, 18(2), e0280942. doi:10.1371/journal.pone.0280942

Scheibenbogen C, Wirth KJ (2025). Key pathophysiological role of skeletal muscle disturbance in post COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): accumulated evidence. Journal of Cachexia, Sarcopenia and Muscle, 16(1), e13669. doi:10.1002/jcsm.13669

Schlömer J, Stein E, Kedor C et al. (2025). Pyridostigmine improves hand grip strength in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Neuroscience, 19, 1637838. doi:10.3389/fnins.2025.1637838

Schutzer SE, Liu T, Tsai CF et al. (2023). Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia are indistinguishable by their cerebrospinal fluid proteomes. Annals of Medicine, 55(1), 2208372. doi:10.1080/07853890.2023.2208372

Shankar K, Wilhelmy J, Curtis A et al. (2025). Oxidative stress is a shared characteristic of ME/CFS and Long COVID. PNAS, 122, e2426564122. doi:10.1073/pnas.2426564122

Stein E, Heindrich C, Wittke K et al. (2025). Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. Lancet Regional Health Europe, 101161. doi:10.1016/j.lanepe.2024.101161

Stussman B, Calco B, Norato G et al. (2024). Mixed methods system for the assessment of post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an exploratory study. BMJ Neurology Open, 6(1), e000529. doi:10.1136/bmjno-2023-000529

Stussman B, Camarillo N, McCrossin G et al. (2025). Post-exertional malaise in Long COVID: subjective reporting versus objective assessment. Frontiers in Neurology, 16, 1534352. doi:10.3389/fneur.2025.1534352

Syed AM, Karius AK, Ma J, Wang P, Hwang PM (2025). Mitochondrial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. Physiology, 40(4), 319–328. doi:10.1152/physiol.00056.2024

Uhde M, Indart AC, Green PHR et al. (2023). Suppressed immune and metabolic responses to intestinal damage-associated microbial translocation in myalgic encephalomyelitis/chronic fatigue syndrome. Brain, Behavior, & Immunity – Health, 32, 100627. doi:10.1016/j.bbih.2023.100627

van Campen CLMC, Rowe PC, Visser FC (2023). Worsening symptoms is associated with larger cerebral blood flow abnormalities during tilt-testing in myalgic encephalomyelitis/chronic fatigue syndrome. Healthcare, 11(24), 3117. doi:10.3390/healthcare11233117

Walitt B, Singh K, LaMunion SR et al. (2024). Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nature Communications, 15, 1615. doi:10.1038/s41467-024-45107-3

Wang P, Ma J, Kim Y et al. (2023). WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome. PNAS, 120(34), e2302738120. doi:10.1073/pnas.2302738120

Wirth KJ, Löhn M (2023). Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and comorbidities: linked by vascular pathomechanisms and vasoactive mediators? Medicina, 59(5), 978. doi:10.3390/medicina59050978

Wirth KJ, Löhn M (2024). Microvascular capillary and precapillary cardiovascular disturbances strongly interact to severely affect tissue perfusion and mitochondrial function in myalgic encephalomyelitis/chronic fatigue syndrome evolving from the post COVID-19 syndrome. Medicina, 60(2), 194. doi:10.3390/medicina60020194

Wirth KJ, Scheibenbogen C (2021a). Pathophysiology of skeletal muscle disturbances in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Journal of Translational Medicine, 19, 162. doi:10.1186/s12967-021-02833-2

Wirth KJ, Scheibenbogen C, Paul F (2021b). An attempt to explain the neurological symptoms of myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Translational Medicine, 19, 471. doi:10.1186/s12967-021-03143-3

Xiong R, Aiken E, Caldwell R et al. (2025). AI-driven multi-omics modeling of myalgic encephalomyelitis/chronic fatigue syndrome. Nature Medicine, 31, 2991–3001. doi:10.1038/s41591-025-03788-3

Translation: Claude Haiku 4.5 (pre-translation), reviewed and finalized by Claude Sonnet. In case of discrepancies, the German version prevails.